<PAGE> 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report: September 9, 1999 Commission File No. 000-22347
(Date of the earliest event reported)
ASCENT PEDIATRICS, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its Charter)
Delaware 04-3047405
- ------------------------------- ---------------------------------
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
187 Ballardvale Street, Wilmington, Massachusetts 01887
- ------------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(978) 658-2500
----------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS
In September 1999, in the course of a telephone discussion between Ascent
Pediatrics, Inc. (the "Company") and the FDA, the FDA advised the Company that
it had agreed to reclassify the deficiency letter the Company had received with
respect to its Abbreviated New Drug Applications, or ANDAs, for Orapred, which
the Company had previously disclosed, from a major deficiency to a minor
deficiency.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: October 7, 1999 ASCENT PEDIATRICS, INC.
/s/ Alan R. Fox
------------------------------
Alan R. Fox
President and Chief Executive
Officer
2
